Purpose: Antagonists of ␣ 1 -adrenergic receptors (␣ 1 ARs) relieve obstructive and irritative symptoms in patients with bladder outlet obstruction. However, to our knowledge mechanisms underlying the relief of irritative symptoms remain unknown. Because bladder ␣ 1d ARs are up-regulated in some rats with bladder outlet obstruction, we investigated the effect of the ␣ 1a AR antagonist 5-methyl urapidil (5MU) vs the ␣ 1a /␣ 1d AR antagonist tamsulosin on urinary frequency in obstructed rats.
Bladder outlet obstruction (BOO), such as that which occurs with benign prostatic hyperplasia, produces 2 types of symptoms, namely obstructive (hesitancy, poor stream, prolonged urination and feelings of incomplete emptying) and irritative (frequency, urgency, nocturia and unstable bladder contractions). Irritative symptoms may persist after removal of the obstruction. 1 The involvement of ␣ 1 -adrenergic receptors (␣ 1 ARs) in BOO is coming under increasing scrutiny. ␣ 1 ARs mediate actions of norepinephrine and epinephrine through 3 ␣ 1 AR subtypes (␣ 1a , ␣ 1b and ␣ 1d ). 2 Nonsubtype selective ␣ 1 AR antagonists relax prostate smooth muscle and relieve obstructive and irritative symptoms. [3] [4] [5] [6] Prostate smooth muscle relaxation is mediated by ␣ 1a ARs 7 and consequently subtype selective ␣ 1a AR antagonists increase urine flow in benign prostatic hyperplasia. 8 However, ␣ 1a AR antagonists do not appear to relieve irritative symptoms. 8 We recently identified ␣ 1d AR mRNA and protein in the human bladder, 9, 10 and reported that bladder ␣ 1d AR mRNA and protein are elevated in a rat model of BOO. 11 We examined the role of ␣ 1d ARs in the development of 1 irritative symptom, that is high urinary frequency, in the rat model of BOO.
MATERIALS AND METHODS Figure 1 shows the study design. Our chronic micturition recording system (CMRS) was used to document the frequency and volume of voiding preceding (CMRS1) and 6 weeks following (CMRS2) surgical intervention to establish obstruction and sham obstruction models. One week following the implantation of osmotic pumps delivering ␣ 1 AR antagonists or their vehicles a final round of CMRS (CMRS3) was done, followed by study of the pressor response to the ␣ 1 AR agonist phenylephrine.
The original study design was for 48 rats, including 12 sham obstructed rats with pumps delivering vehicle (water in Accepted for publication February 20, 2004 6 and propylene glycol [PG] in 6), 12 obstructed rats with pumps delivering vehicle (water in 6 and PG in 6), 12 obstructed rats with pumps delivering tamsulosin dissolved in water and 12 obstructed rats with pumps delivering 5-methyl urapidil (5MU) dissolved in PG. Rats were added to the study to replace losses due to postoperative mortality and ensure that there were at least 6 rats in the 5MU and tamsulosin groups with a bladder mass of greater than 500 mg (the mass previously shown to result in increase ␣ 1d AR expression). A total of 64 female Sprague-Dawley rats (Charles River; Wilmington, Massachusetts) weighing 175 to 200 gm at acquisition were studied. Figure 1 shows the final numbers of sham obstructed and obstructed rats with pumps delivering each substance.
The CMRS has been described fully. 11 Briefly, rats were housed for 3 days each on 3 separate occasions in metabolic cages with urine accumulation into separate collectors connected to DP8-47 pressure transducers (BEC Controls, Davenport, Iowa). Transducer outputs were measured every 30 seconds and converted to volumes using calibration data. If the change in volume since the preceding period was greater than 0.1 ml, time and micturition volume were recorded. Using these data volumes per micturition and urinary frequencies were determined.
Following CMRS1 rats were anesthetized with halothane and the abdomen was opened to expose the bladder. A 3-zero silk suture was placed under the urethra, a 1.09 mm diameter tube was placed upon the urethra, the suture was tied without compressing the urethra and the polyethylene tube was removed. In sham obstructed rats the suture was also removed. Subsequently the abdominal wound was closed.
Following CMRS2 the rats were anesthetized with isoflurane and Alzet osmotic pumps (2ML2, Durect Corp., Cupertino, California) were implanted subcutaneously. These pumps run for up to 2 weeks at 5 l per hour. Pumps contained tamsulosin in water, 5MU in PG, water or PG. Prior pharmacokinetic studies performed at the laboratory of one of us (CK) showed a total plasma clearance and volume of distribution of 80 ml/kg per minute and 148 ml/kg for tamsulosin vs 14 ml/kg per minute and 32 ml/kg for 5MU, respectively. These parameters were used to calculate the amounts of drugs needed to give a steady-state plasma concentration of 15 ng/ml for tamsulosin and 50 ng/ml for 5MU, which were 1.72 mg/kg daily for tamsulosin and 2.66 mg/kg daily for 5MU. After 1 week the rats underwent CMRS3.
A day later dose-response study of pressor response to the ␣ 1 AR agonist phenylephrine (3 to 300 g/kg) was performed. Rats were anesthetized subcutaneously with urethane (Sigma Chemical Co., St. Louis, Missouri) (1.3 gm/kg) and a PE-50 catheter was placed in the jugular vein for phenylephrine administration. Phenylephrine solutions prepared in distilled water were administered in a volume of 250 l, followed by a 100 l saline flush. A PE-90 catheter was placed in the carotid artery and connected to an Ohmeda P23XL-1 pressure transducer (Gould, Valley View, Ohio). Data were sampled at 50 Hz using a PCI-MIO-16XE10 data acquisition board (National Instruments, Austin, Texas). A program written in LabVIEW (National Instruments) was used for analysis. Phenylephrine administration caused a transient increase in mean arterial pressure. The peak elevation in mean arterial pressure above the immediate preinjection value was measured.
Statistical analysis. Any rat urinary frequency and volume per micturition depend on many factors in addition to experimental interventions, including water and food intake, body mass and other biological tendencies. Multiple regression analysis was applied to our data to account for the effects of such variables in our small groups. When comparing drugs to vehicle, we included indicator variables for each drug. Hypothesis tests for the regression coefficients were made using 1-tailed t tests (because relative to vehicle ␣ 1 AR antagonist treatment decreases frequency or has no effect) with df equal to sample size minus the number of parameters in the model. Model evaluations were performed by analyzing residuals. Analyses were performed using S-Plus (Insightful Corp., Seattle, Washington).
RESULTS
The mean bladder mass Ϯ SEM of rats that underwent obstruction surgery was significantly greater than that of sham obstructed rats (663 Ϯ 88 vs 136 Ϯ 15 mg, p Ͻ0.001). However, many bladders in the obstructed group were not hypertrophied. Figure 2 shows bladder mass at sacrifice after CMRS3 on a log scale to show indicate wide dispersion of bladder masses and the large number of low mass bladders found in the obstructed rat group, of which many were within the range of sham obstructed bladders. The dotted line at 255 mg marks the limit of sham obstructed rat bladders and that Figure 3 shows the change in urinary frequency with obstruction in different subsets. Sham obstructed rats showed a decrease, as did obstructed bladders with a mass of less than 255 mg (small BOO). These 2 groups were considered together as all less than 255 mg (11 sham obstructed, range 92 to 255 mg, and 13 ostensibly obstructed, range 128 to 217). Obstructed rats overall (all BOO) showed almost no change in frequency, whereas obstructed rats with a bladder masses of above 255 mg (BOO greater than 255) showed an increase and those with a bladder mass of above 500 mg (BOO greater than 500) showed a larger increase. The change in frequency in the BOO greater than 500 group was significantly different from that in the all less than 255 group (vs all less than 255, p ϭ 0.01).
␣1-ADRENERGIC RECEPTOR SUBTYPE SELECTIVE ANTAGONISTS AND URINARY TRACT
Study of the effects of ␣ 1 AR antagonists on urinary frequency was limited to rats with a bladder mass of greater than 500 mg because they showed elevated urinary frequency ( fig. 3 ) and were expected to show elevations in ␣ 1d AR relative to ␣ 1a AR. 11 Because obstruction surgery produced only 3 rats with bladders this large in each of the BOO water and BOO PG groups ( fig. 2 ), these 2 vehicle groups were combined after statistical analysis showed no significant difference between them. There was a high correlation of urinary frequency with water intake (r ϭ 0.62), a lower correlation with food intake (r ϭ 0.24) and none with body mass (r ϭ 0.08). Accordingly water intake was used as a predictor on multiple regression analysis. Urinary frequency at CMRS2 (1 week before) was also used as a predictor to help control for unspecified factors intrinsic to individual rats.
To ensure that no rats with anomalous urinary frequency values would distort the multiple regression analysis we examined the relationship between urinary frequency at CMRS2 and CMRS3 in all rats ( fig. 4) . This plot showed a strong linear relationship between the 2 frequencies (slope 1.03). However, 1 vehicle rat departed strongly from that linear relationship increasing from 30 micturitions daily before pump insertion to 112 micturitions daily 1 week after pump insertion. The effect of this anomalous rat was to exaggerate CMRS3 frequency in the vehicle group. This rat also greatly increased the estimated effects of drugs on regression analysis. Accordingly this rat was removed from the data set.
The table lists results of multiple regression analysis. CMRS2 frequency was a strong predictor of CMRS3 frequency (p Ͻ0.0001), as was water intake (p ϭ 0.108). The coefficients of the effects of tamsulosin relative to vehicle and 5MU relative to vehicle indicate the decrease in the number of micturitions events daily attributable to tamsulosin (23, p ϭ 0.026) and 5MU (18, p ϭ 0.066), when controlling for frequency at CMRS2 and water intake.
A dose-response study of the effect of phenylephrine on mean arterial pressure in rats was performed after CMRS3 ( fig. 5 ). Phenylephrine induced marked transient elevations in mean arterial pressure in rats with vehicle pumps, whether sham obstructed or obstructed. Rats with 5MU pumps showed approximately a 4-fold shift of the phenylephrine dose-response curve to the right, while rats with tamsulosin pumps showed a much larger shift to the right (perhaps 40-fold, although the curve was so nearly flat as to leave considerable uncertainty).
DISCUSSION
While nonsubtype selective ␣ 1 AR antagonists relieve obstructive and irritative symptoms of BOO, ␣ 1a selective antagonists relieve only obstructive symptoms in humans. 8 This finding suggests the hypothesis that another ␣ 1 AR subtype, most likely ␣ 1d , is important in mediating irritative symptoms. The central finding of the current study, that the combined ␣ 1a /␣ 1d AR antagonist tamsulosin decreases urinary frequency more than the ␣ 1a AR selective antagonist 5MU in high mass obstructed rat bladders, supports that hypothesis.
The variability of bladder mass in the rat obstruction model is well known. 12 Given that our study was designed to test the importance of ␣ 1d ARs in the irritative symptom of high urinary frequency, it seemed prudent to examine hyper- fig. 4 ) and coefficients can be interpreted as number of micturitions daily by which each drug changed urinary frequency vs vehicle treated rats.
Effect of drugs on urinary frequency at CMRS3
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trophied bladders in which ␣ 1d AR protein expression would be expected. We previously noted a shift in predominance from ␣ 1a AR to ␣ 1d AR mRNA and de novo ␣ 1d AR protein expression in hypertrophied rat bladders after obstruction, particularly in bladders with a mass more than 5-fold greater than the mean of sham bladder masses. 11 In the current study rats with similarly hypertrophied bladders also demonstrated significantly increased urinary frequency prior to drug therapy ( fig. 3) , further justifying our decision to focus on this group only.
Testing the importance of the ␣ 1d ARs in high urinary frequency presented 2 major difficulties. 1) There is no ␣ 1d AR antagonist available that is selective enough in vivo. (The standard highly selective ␣ 1d AR selective antagonist BMY7378 is a partial agonist at 5-HT 1A receptors in the same dose range 13 and 5-HT 1A receptor agonists affect micturition in rats.) 2) Drug uroselectivity is different in rats 14 than in other species (rabbits, dogs and humans). 15 We chose the combined ␣ 1a /␣ 1d AR antagonist tamsulosin and the ␣ 1a AR antagonist 5MU, each demonstrating a greater than 10-fold higher affinity and antagonist potency compared to other ␣ 1 AR subtypes. 16, 17 With respect to the in vivo selectivity of these drugs in the rat, data on conscious rats 14 showed that tamsulosin has higher efficacy and potency to decrease uterine pressure than 5MU but the selectivity of 5MU to decrease uterine pressure compared to blood pressure in rats was higher than for tamsulosin (7-fold vs nil). 14 These data were confirmed for tamsulosin in a separate study. 18 To use these small selectivity differences of the 2 drugs in our rat model we selected dose levels for infusion of these drugs that were deduced from published studies. 14, 18 Verification of the adequacy of obtained drug exposure in the rats was done by analysis of the shift in the phenylephrine doseresponse curve for blood pressure responses. In the rat ␣ 1a AR and ␣ 1d AR subtypes are present in the conduit and resistance vessels and, therefore, they may be important in hemodynamic responses. 19 In this respect it is not surprising that tamsulosin with its affinity for ␣ 1a AR and ␣ 1d AR subtypes has more of a blood pressure effect than 5MU ( fig. 5) .
Apart from showing firm hemodynamic effects, tamsulosin also showed a statistically significant decrease in urinary frequency in rats with a high bladder mass. The relatively stronger effect of 5MU on the decrease in urinary frequency compared to hemodynamics in our study, which is in line with the in vivo uroselectivity data of Martin et al, 14 unfortunately does not allow us to draw a firm conclusion about the identity of the ␣ 1 AR subtype functionally involved in the increased urinary frequency in our model. Assuming that the drug plasma levels in our study were in agreement with those obtained in the pharmacokinetic study, the steady state levels for tamsulosin and 5MU would translate into concentrations for the ␣ 1a AR that are about 1,200-fold the pA 2 for 5MU, about 770-fold the pA 2 for tamsulosin, to about 2 and 0.8-fold the pA 2 level for ␣ 1b AR, and to about 10 and 75-fold the pA 2 level for ␣ 1d AR, respectively. This shows that bladder frequency data in our study do not match with drug effects at ␣ 1b ARs (these ARs were indeed not found in the rat bladders in our prior study 1 ) . In this reasoning potency at the ␣ 1d AR is higher for tamsulosin, while at the ␣ 1a AR 5MU is the more effective drug. Looking at the current results, this implies that there is a stronger involvement of ␣ 1d AR in hemodynamic and the bladder effects, while ␣ 1b AR is not likely to be significantly involved in hemodynamic and bladder effects.
This does not apply in humans, in whom ␣ 1 AR mediated pressor effects primarily depend on ␣ 1a AR in young individuals with increasing importance of the ␣ 1b subtype with aging. 20 Supporting this hypothesis, nonsubtype selective ␣ 1 AR antagonists decrease mean arterial pressure in humans of all ages, whereas the ␣ 1a /␣ 1d AR antagonist tamsulosin has been shown to have minimal blood pressure effects in older individuals, presumably due to its lack of ␣ 1b AR antagonist effects. With respect to the role of ␣ 1d ARs in human bladders data are not yet available. Assuming some analogy between humans and rats in the bladder pathophysiology of BOO, there could be a role for ␣ 1d AR selective drugs to decrease urinary frequency in human BOO. In humans this should occur without an effect on hemodynamics.
CONCLUSIONS
Our previous finding of enhanced ␣ 1d AR expression in obstructed rats with markedly hypertrophied bladders 11 and our current finding of a decrease in urinary frequency in such rats with tamsulosin more than with 5MU support the hypothesis that the ␣ 1d ARs are mechanistically involved in the development of irritative symptoms and they are plausible targets for therapeutic intervention. If these findings are confirmed in humans, targeting ␣ 1d AR may provide a new ␣1-ADRENERGIC RECEPTOR SUBTYPE SELECTIVE ANTAGONISTS AND URINARY TRACT FUNCTION therapeutic approach to controlling bladder irritative symptoms associated with BOO.
